Exploring Ra Medical Systems, Inc. (RMED) Investor Profile: Who’s Buying and Why?

Curious who's backing Ra Medical Systems, Inc. (RMED) and why the stock is commanding attention despite recent volatility? At a current price of $2.235 (down $0.23 or -0.09% from the prior close) with an opening print of $2.55, an intraday high/low of $2.45/$2.20 and volume of 59,984 shares (last trade Monday, December 15, 17:15:00 PST), RMED sits at the intersection of retail enthusiasm for its DABRA catheter, concentrated institutional ownership and strategic dealmaking: former Catheter Precision stakeholders now control roughly 87.7% of equity on a fully diluted basis after the January 2023 merger, the company raised about $6.2M from warrant exercises in July 2022 and completed an $8M private placement in March 2023 - while moves like the August 2021 dermatology divestiture and active participation from venture, private equity and healthcare funds have shaped a shareholder base that's larger than the industry average and worth a closer look in the pages that follow.

Ra Medical Systems, Inc. (RMED) - Who Invests in Ra Medical Systems, Inc. (RMED) and Why?

• Retail value investors attracted by low absolute share price and perceived deep value relative to historical levels.
• Speculative traders and momentum investors chasing intraday swings and low-float volatility.
• Specialty biotech investors focused on device/dermatology niches who bet on recovery from past operational setbacks.
• Short-sellers and tactical hedge funds targeting balance-sheet risk, recurring losses, or potential dilution.
• Event-driven investors positioning ahead of clinical updates, regulatory news, or strategic partnerships.

• Balance sheet and cash runway: investors monitor cash burn, debt, and any recent or pending equity raises that could dilute holders.
• Regulatory and clinical milestones: near-term trial updates or FDA interactions materially change risk/reward.
• Commercial traction: adoption rates for Ra Medical's laser-based vascular and dermatology products drive revenue visibility.
• Share float and liquidity: relatively small intraday volumes can amplify price moves, attracting momentum traders.

Institutional Ownership and Major Shareholders of Ra Medical Systems, Inc. (RMED)

• Individual investors - drawn to innovation and potential upside from minimally invasive PAD (peripheral artery disease) therapies and outcomes data improvements.
• Institutional investors - target RMED for growth exposure in the vascular-device vertical and potential consolidation plays within medical devices.
• Healthcare-focused mutual funds - use RMED to add high-beta, specialized-device exposure to diversified health portfolios.
• Private equity - views RMED as a candidate for scaling manufacturing, commercial expansion, and margin improvement.
• Impact investors - support RMED's work addressing underserved vascular conditions and improving patient quality of life.
• Strategic investors - larger medtech companies evaluate RMED for partnerships, licensing, or tuck-in acquisitions to expand product lines.

• Vanguard Group - 4.2% (~966,000 shares)
• BlackRock, Inc. - 3.8% (~874,000 shares)
• Renaissance Technologies - 3.0% (~690,000 shares)
• State Street Global Advisors - 2.5% (~575,000 shares)
• Insiders (combined executives & directors) - 6.5% (~1,495,000 shares)

• Growth thesis: niche leadership in catheter-based PAD interventions with potential for broader vascular applications.
• Exit/return potential: private equity and strategic buyers can consolidate tech into larger commercial platforms.
• Portfolio fit: healthcare funds and institutions seeking asymmetric returns from medical-device innovation.
• Impact & outcomes: investors focused on patient benefit see value in less-invasive therapies addressing unmet needs.

Ra Medical Systems, Inc. (RMED) - Key Investors and Their Impact on Ra Medical Systems, Inc. (RMED)

• Post-merger concentration: the January 2023 merger with Catheter Precision resulted in former Catheter Precision stakeholders owning ~87.7% of RMED equity on a fully diluted basis, immediately making those stakeholders the controlling owners.
• Warrant financing impact: exercise of previously issued warrants in July 2022 generated approximately $6.2 million of cash proceeds, altering share distributions among existing holders and new warrant-exercise participants.
• Institutional footprint: institutional investors currently hold a substantial portion of RMED's outstanding shares, a level that is above the typical medical-device industry average and indicative of pronounced institutional confidence.
• Early-stage VC presence: several venture-capital and growth-equity firms that participated in RMED's earlier funding rounds remain material holders, reflecting multi-year investment horizons and alignment with strategic growth plans.

• Control dynamics: with ~87.7% held by former Catheter Precision stakeholders on a fully diluted basis, shareholder voting power and board composition became concentrated, enabling decisive governance and strategic direction changes post-merger.
• Liquidity and capital: the $6.2M raised via warrant exercises (July 2022) improved near-term liquidity and influenced dilution patterns, reducing the relative ownership of non-exercising holders.
• Comparative institutional intensity: RMED's institutional ownership percentage (inclusive of large strategic holders) surpasses the common medical-device company average, often cited in the 40-60% range for the sector, underscoring heightened institutional interest relative to peers.
• Investor motivations:

• Strategic control and consolidation - Catheter Precision stakeholders sought control to integrate complementary IP and commercial capabilities.
• Value creation via restructuring - institutional and VC investors showing conviction around post-merger operational improvements and potential commercialization scale-up.
• Event-driven opportunity - some investors were attracted by the financing events (warrant exercises) and transactional re-pricing, providing entry points ahead of integration milestones.

Ra Medical Systems, Inc. (RMED) - Market Impact and Investor Sentiment

• Executive leadership and governance: David Jenkins (CEO/founder of Catheter Precision) was appointed Executive Chairman of RMED's Board post-merger, bringing medical-device startup operating experience and credibility to the boardroom and investor conversations.
• Capital markets and placements: Ladenburg Thalmann & Co. Inc. served as exclusive placement agent for RMED's March 2023 private placement, which raised $8.0 million, providing crucial near-term liquidity.
• Specialty capital & advisory: TopHat Capital, LLC (co-founded by Mr. Kraws) has participated in RMED's financial strategy and capital-raising initiatives, adding boutique capital expertise.
• International/private equity interest: Grannus Securities Pty Ltd., an Australia-based private equity fund, has invested in RMED, signaling cross-border investor interest in the company's technology and growth potential.
• Strategic healthcare partnerships: PDK Healthcare Innovations LLC has partnered with RMED to provide strategic guidance and business development support.
• Investor communications: LHA Investor Relations has managed RMED's investor relations activities to improve shareholder communications and market visibility.

• Market signals: The March 2023 $8M placement signaled immediate financing needs addressed via PIPE-style capital, which typically tempers short-term dilution concerns while extending runway for commercialization or restructuring.
• Sentiment drivers: Active board additions with device commercialization experience (e.g., Jenkins) improve institutional investor comfort on execution risk; international PE participation (Grannus) indicates diversified investor interest beyond U.S. retail flows.
• Liquidity and trading: Placement-agency-led raises and visible IR programs (Ladenburg, LHA) often coincide with management efforts to stabilize trading and re-attract analyst / investor attention.